Loading...
Anti-TGFB Recombinant Antibody Products
Loading...Anti-TGFB Products
- Human Anti-TGFB Recombinant Antibody (HPAB-0019-YC) (HPAB-0019-YC)
-
- Species Reactivity: Human, Mouse
- Type: Human IgG
- Application: Neut
- Human Anti-TGFB Recombinant Antibody (HPAB-0020-YC) (HPAB-0020-YC)
-
- Species Reactivity: Human
- Type: Human IgG4
- Application: Neut
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: ELISA, FC
- Human Anti-TGFB Recombinant Antibody; scFv Fragment (HPAB-0019-YC-S(P)) (HPAB-0019-YC-S(P))
-
- Species Reactivity: Human, Mouse
- Type: Human scFv
- Application: Neut
- Human Anti-TGFB Recombinant Antibody; scFv Fragment (HPAB-0020-YC-S(P)) (HPAB-0020-YC-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: Neut
- Human Anti-TGFB Recombinant Antibody; Fab Fragment (HPAB-0019-YC-F(E)) (HPAB-0019-YC-F(E))
-
- Species Reactivity: Human, Mouse
- Type: Human Fab
- Application: Neut
- Human Anti-TGFB Recombinant Antibody; Fab Fragment (HPAB-0020-YC-F(E)) (HPAB-0020-YC-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: Neut
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is at the forefront of developing high-quality anti-TGFβ recombinant antibody products, engineered to meet the diverse and stringent demands of global research and therapeutic development. Our comprehensive portfolio offers unparalleled specificity and efficacy, empowering scientists worldwide to accelerate breakthroughs in critical disease areas.
TGFB: a Versatile Target for Cancer Immunotherapy and Fibrotic Diseases
Transforming Growth Factor-β (TGF-β) is a pleiotropic cytokine with critical roles in cell proliferation, differentiation, apoptosis, and immune responses. While it can act as a tumor suppressor in early cancer stages, it often promotes tumor progression, metastasis, and drug resistance in advanced cancers by shaping the tumor microenvironment. Beyond oncology, dysregulated TGF-β signaling is a central driver of fibrogenesis across various organs, leading to excessive extracellular matrix accumulation and organ dysfunction. Understanding and modulating TGF-β pathways is therefore crucial for developing novel treatments for cancer and fibrotic disorders.
Alternative Names
Transforming growth factor beta; TGF-β; TGFbeta; TGFβ.
Background
This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. Many cells have TGFB receptors, and the protein positively and negatively regulates many other growth factors. The secreted protein is cleaved into a latency-associated peptide (LAP) and a mature TGFB1 peptide, and is found in either a latent form composed of a TGFB1 homodimer, a LAP homodimer, and a latent TGFB1-binding protein, or in an active form composed of a TGFB1 homodimer. The mature peptide may also form heterodimers with other TGFB family members. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease.
Anti-TGFB rAb Products
Creative Biolabs offers a series of anti-TGFB recombinant antibodies that are meticulously engineered to deliver superior performance. These antibodies exhibit high affinity and specificity, thereby facilitating the precise targeting of TGFB isoforms. Leveraging advanced recombinant technology, our antibody production ensures exceptional batch-to-batch consistency and purity, attributes that are indispensable for obtaining reliable and reproducible experimental outcomes and for their potential utility in clinical applications.
Table 1. Featured anti-TGFB recombinant antibody products at Creative Biolabs.
| Cat. No. | Product Name | Target Species | Host Species | Applications |
| HPAB-0019-YC | Human Anti-TGFB Recombinant Antibody (HPAB-0019-YC) | Human, Mouse | Human IgG | Neut |
| HPAB-0020-YC | Human Anti-TGFB Recombinant Antibody (HPAB-0020-YC) | Human | Human IgG4 | Neut |
| HPAB-0019-YC-S(P) | Human Anti-TGFB Recombinant Antibody; scFv Fragment (HPAB-0019-YC-S(P)) | Human, Mouse | Human scFv | Neut |
| HPAB-0020-YC-S(P) | Human Anti-TGFB Recombinant Antibody; scFv Fragment (HPAB-0020-YC-S(P)) | Human | Human scFv | Neut |
| HPAB-0019-YC-F(E) | Human Anti-TGFB Recombinant Antibody; Fab Fragment (HPAB-0019-YC-F(E)) | Human, Mouse | Human Fab | Neut |
Creative Quality Control
At Creative Biolabs, we rigorously adhere to quality control protocols when performing production. The anti-TGFB recombinant antibodies produced by our facility are subjected to comprehensive, multi-faceted analytical procedures, encompassing techniques such as ELISA, flow cytometry, and bioactivity assays, thereby ensuring their optimal performance. Furthermore, each production lot undergoes meticulous validation for purity, specificity, and functional activity, which collectively guarantees the provision of consistent, high-quality reagents essential for diverse research and development applications.
Customer Reviews
Human Anti-TGFB Recombinant Antibody (HPAB-0020-YC) (CAT#: HPAB-0020-YC)
Mouse Anti-TGFB Recombinant Antibody (clone YC140) (MOB-086LC)
Human Anti-TGFB Recombinant Antibody (HPAB-0019-YC) (CAT#: HPAB-0019-YC)
rAb Production
Our anti-TGFB recombinant antibodies are produced using state-of-the-art recombinant technology and mammalian expression systems, ensuring native folding and post-translational modifications for optimal biological activity. This robust production platform allows for scalable manufacturing while maintaining stringent quality standards, delivering a consistent supply of high-performance antibodies for diverse research needs.
Featured Anti-TGFB Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-TGFB recombinant antibody production.
Fig.2 Gram-scale anti-TGFB recombinant antibody production.
rAb Modalities
Creative Biolabs offers anti-TGFB recombinant antibodies in multiple modalities, including monoclonal, bispecific, engineered antibody fragments, and many others, providing versatile tools for various research and therapeutic strategies.
Fig.3 Full-length anti-TGFB recombinant antibody production and modalities.
TGFB-Targeted Drug Information
Table 2. Public drug targeting TGFB.
| Company | Research phase | Classification | Condition |
|
Acceleron Pharma (Merck & Co) Celgene Massachusetts General Hospital M.D. Anderson Cancer Center (MD Anderson Cancer Center) Merck & Co (Originator) |
Launched - 2024 |
Fc Fusion Proteins Polypeptides, from 41 AA |
Anemia, chemotherapy-induced Anemia in chronic kidney disease Bone disorders Cancer Diamond-Blackfan anemia End-stage renal disease Eye Disorders Hypertension, pulmonary arterial Multiple myeloma Myeloproliferative diseases Osteoporosis Osteoporosis, postmenopausal Thalassemia, beta |
|
Acceleron Pharma (Merck & Co) Bristol-Myers Squibb Celgene Merck & Co (Originator) |
Launched - 2019 |
Fc Fusion Proteins Polypeptides, from 41 AA |
Anemia Eye Disorders Myelodysplasia Myelofibrosis Thalassemia, alpha Thalassemia, beta |
| Curative (Originator) | Phase III |
Growth Factors Multi-Component Products Polypeptides, from 41 AA |
Lesion, skin |
| HCW Biologics (Originator) | Phase II |
Fusion Proteins Polypeptides, from 41 AA |
Cancer Cancer, breast Cancer, colorectal Cancer, ovary Cancer, pancreas Cancer, prostate Cancer, solid tumor Diabetes type 2 Melanoma |
|
Agenus (Originator) Gilead |
Phase II |
Cancer Immunotherapy Fusion Proteins Humanized Monoclonal Antibodies Immunoconjugates Polypeptides, from 41 AA |
Cancer Cancer, colorectal Cancer, pancreas (ductal adenocarcinoma) Cancer, solid tumor |
|
EMD Serono GlaxoSmithKline (GSK) Merck KGaA (Originator) National Cancer Institute (NCI) (National Cancer Institute) |
Phase II |
Cancer Immunotherapy Fusion Proteins Immunoconjugates Polypeptides, from 41 AA Transforming Growth Factor-beta (TGF-beta) |
Cancer Cancer, bile duct Cancer, biliary Cancer, cervix Cancer, colon (adenocarcinoma) Cancer, colorectal Cancer, gallbladder Cancer, head and neck Cancer, hepatobiliary Cancer, lung (non-small cell) (NSCLC) Cancer, metastatic (to brain) Cancer, ovary Cancer, pancreas (adenocarcinoma) Cancer, prostate Cancer, prostate (adenocarcinoma), metastatic Cancer, rectum (adenocarcinoma) Cancer, small intestine Cancer, solid tumor Cancer, stomach Cholangiocarcinoma Female reproductive system cancer Genitourinary cancer Glioblastoma multiforme Mesothelioma, malignant Neuroblastoma Sarcoma Triple negative breast cancer |
| Lilly (Originator) | Phase II | Monoclonal Antibodies |
Chronic kidney disease Diabetic nephropathy |
|
Astellas Pharma (Originator) Novartis (Originator) Oncogen Universitair Medisch Centrum Groningen |
Phase II |
Polypeptides, from 41 AA Recombinant proteins Transforming Growth Factor-beta (TGF-beta) |
Cancer Lesion, skin Mucositis, chemotherapy- or radiotherapy-induced Other dermatological disorders |
|
Insmed (Originator) Sanofi Genzyme |
Phase II |
Polypeptides, from 41 AA Recombinant proteins Transforming Growth Factor-beta (TGF-beta) |
Lesion, skin |
| Betta Pharmaceuticals (Originator) | Phase I/II |
Bispecific Antibody Fusions Cancer Immunotherapy Fusion Proteins Humanized Monoclonal Antibodies Polypeptides, from 41 AA Single-Domain Antibodies |
Cancer, colorectal Cancer, solid tumor |
| Suzhou Zelgen Biosciences (Originator) | Phase I/II |
Bispecific Antibodies Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, solid tumor |
| Transcenta (Originator) | Phase I/II |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, prostate Cancer, solid tumor |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
At Creative Biolabs, we are dedicated to supporting your scientific endeavors with cutting-edge solutions. Explore our comprehensive range of anti-TGFB recombinant antibody products today and discover how they can empower your next breakthrough. For detailed product information or to discuss your specific project requirements, please do not hesitate to get in touch with us.


Inflammatory Bowel Diseases